Mas Amira Idayu Abdul Razak
◽
Haslinda Abdul Hamid
◽
Raja Nor Izawati Raja Othman
◽
Shaik Alaudeen Mohd Moktar
◽
Azizi Miskon
Introduction:
Bioconjugations are swiftly progressing and are being applied to solve several limitations of conventional drug delivery systems (DDS) such as lack of water solubility, non-specific, and poor bioavailability. The main
goals of DDS are to achieve greater drug effectiveness and minimize toxicity to the healthy tissues.
Objectives:
In this study, D-glucose was conjugated with eugenol to target the cancer cells. To identify the implication of
the anticancer effect, osteosarcoma (K7M2) cells were cultured and the anti-proliferative effect was performed using MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay] test in order to evaluate the viability and toxicity on
cells with various concentrations of eugenol and D-glucose-eugenol conjugate in 24-hour incubation.
Results:
It was found that, the successful confirmation of the conjugation between D-glucose and eugenol was obtained by 1
H NMR spectroscopy. MTT assay showed inhibitory concentration (IC50 value) of D-glucose-eugenol was at 96.2 µg/ml
and the decreased of osteosarcoma cell survival was 48%.
Conclusion:
These findings strongly indicate that K7M2 cells would be affected by toxicity of D-glucose-eugenol. Therefore, the present study suggests that D-glucose-eugenol has high potential to act as an anti-proliferative agent who may
promise a new modality or approach as the drug delivery treatment for cancer or chemotherapeutic agent.
The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties
